{
    "info": {
        "nct_id": "NCT03576612",
        "official_title": "Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined with Standard of Care for Newly Diagnosed High-Grade Gliomas",
        "inclusion_criteria": "* Patients must have operable brain tumor presumed to be high grade glioma (HGG) based on clinical and radiologic evaluation, where a gross total surgical resection of the contrast-enhancing area is intended; pathologic confirmation of HGG must be made at the time of surgery prior to AdV-tk injection, if not previously determined\n* Patients must have a Karnofsky performance status >= 70% (i.e. the patient must be able to care for himself/herself with occasional help from others)\n* Absolute neutrophil count >= 1,500/uL\n* Platelets >= 100,000/uL\n* Hemoglobin >= 9 g/dL\n* Total bilirubin =< 1.5 x institutional upper limit of normal (ULN), (except for patients with known Gilbert's syndrome who must have normal direct bilirubin)\n* Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT)/alanine aminotransaminase (ALT) serum glutamate pyruvate transaminase (SGPT) =< 3.0 x institutional ULN\n* Creatinine =< institutional ULN\n* Calculated creatinine clearance >= 40 ml/min (use a modified Cockcroft-Gault equation)\n* Activated partial thromboplastin time/partial thromboplastin time (APTT/PTT) =< 1.5 x institutional ULN\n* Patients must be able to provide written informed consent\n* Patients must have magnetic resonance imaging (MRI) within 14 days of starting treatment; patients must be able to tolerate MRI\n* Women of childbearing potential must agree to have a negative serum pregnancy test within 24 hours prior to treatment start; women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study treatment, and through at least 5 months after the last dose of study drug; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; sexually active men of reproductive potential who are partners of women with reproductive potential must also agree to use adequate contraception prior to the study, for the duration of study participation, and through at least 7 months after the last dose of study drug; adequate methods of effective birth control include sexual abstinence (men, women); vasectomy; or a condom with spermicide (men) in combination with barrier methods, hormonal birth control or intrauterine device (IUD) (women)\n* Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder; patients with prior malignancies must be disease-free for >= two years; patients with low-risk prostate cancer on active surveillance are eligible\n* Patients must be able to swallow oral medications\n* Patients must not have received prior radiation therapy, chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, tumor infiltrating lymphocyte [TIL], lymphokine-activated killer [LAK] or gene therapy), or hormonal therapy for their brain tumor; glucocorticoid therapy is allowed\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Patients receiving any other investigational agents are ineligible\n* Patients with a history of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to valacyclovir, acyclovir, or temozolomide are ineligible; the valacyclovir and temozolomide package inserts can be referenced for more information\n* Patients with a history of severe hypersensitivity reaction to any monoclonal antibody are ineligible\n* Patients who require therapy with systemic immunosuppressive drugs except corticosteroids are ineligible\n* Patients with a history of active autoimmune disease requiring treatment in the past 2 years are ineligible\n* Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active liver disease or active hepatitis, or psychiatric illness/social situations that would limit compliance with study requirements, are ineligible\n* Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents through 1 week after receiving the last dose of study drugs\n* Patients who are known to be human immunodeficiency virus (HIV) positive are ineligible",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Patients must have a Karnofsky performance status >= 70% (i.e. the patient must be able to care for himself/herself with occasional help from others)",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky performance status >= 70%",
                    "criterion": "Karnofsky performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count >= 1,500/uL",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count >= 1,500/uL",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets >= 100,000/uL",
            "criterions": [
                {
                    "exact_snippets": "Platelets >= 100,000/uL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin >= 9 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT)/alanine aminotransaminase (ALT) serum glutamate pyruvate transaminase (SGPT) =< 3.0 x institutional ULN",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) ... =< 3.0 x institutional ULN",
                    "criterion": "aspartate aminotransferase (AST) / serum glutamic-oxaloacetic transaminase (SGOT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x institutional ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransaminase (ALT) serum glutamate pyruvate transaminase (SGPT) ... =< 3.0 x institutional ULN",
                    "criterion": "alanine aminotransaminase (ALT) / serum glutamate pyruvate transaminase (SGPT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x institutional ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 x institutional upper limit of normal (ULN), (except for patients with known Gilbert's syndrome who must have normal direct bilirubin)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x institutional upper limit of normal (ULN)"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with known Gilbert's syndrome who must have normal direct bilirubin",
                    "criterion": "direct bilirubin (in patients with known Gilbert's syndrome)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "normal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine =< institutional ULN",
            "criterions": [
                {
                    "exact_snippets": "Creatinine =< institutional ULN",
                    "criterion": "creatinine level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "institutional ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Activated partial thromboplastin time/partial thromboplastin time (APTT/PTT) =< 1.5 x institutional ULN",
            "criterions": [
                {
                    "exact_snippets": "Activated partial thromboplastin time/partial thromboplastin time (APTT/PTT) =< 1.5 x institutional ULN",
                    "criterion": "activated partial thromboplastin time (APTT/PTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "institutional ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be able to provide written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Patients must be able to provide written informed consent",
                    "criterion": "ability to provide written informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Calculated creatinine clearance >= 40 ml/min (use a modified Cockcroft-Gault equation)",
            "criterions": [
                {
                    "exact_snippets": "Calculated creatinine clearance >= 40 ml/min (use a modified Cockcroft-Gault equation)",
                    "criterion": "calculated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "ml/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "modified Cockcroft-Gault equation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have magnetic resonance imaging (MRI) within 14 days of starting treatment; patients must be able to tolerate MRI",
            "criterions": [
                {
                    "exact_snippets": "magnetic resonance imaging (MRI) within 14 days of starting treatment",
                    "criterion": "magnetic resonance imaging (MRI)",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients must be able to tolerate MRI",
                    "criterion": "MRI tolerance",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have operable brain tumor presumed to be high grade glioma (HGG) based on clinical and radiologic evaluation, where a gross total surgical resection of the contrast-enhancing area is intended; pathologic confirmation of HGG must be made at the time of surgery prior to AdV-tk injection, if not previously determined",
            "criterions": [
                {
                    "exact_snippets": "operable brain tumor",
                    "criterion": "brain tumor",
                    "requirements": [
                        {
                            "requirement_type": "operability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "presumed to be high grade glioma (HGG) based on clinical and radiologic evaluation",
                    "criterion": "high grade glioma (HGG)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "clinical evaluation",
                                "radiologic evaluation"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "gross total surgical resection of the contrast-enhancing area is intended",
                    "criterion": "gross total surgical resection of the contrast-enhancing area",
                    "requirements": [
                        {
                            "requirement_type": "intention",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pathologic confirmation of HGG must be made at the time of surgery prior to AdV-tk injection, if not previously determined",
                    "criterion": "pathologic confirmation of HGG",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the time of surgery prior to AdV-tk injection"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder; patients with prior malignancies must be disease-free for >= two years; patients with low-risk prostate cancer on active surveillance are eligible",
            "criterions": [
                {
                    "exact_snippets": "no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder",
                    "criterion": "concurrent malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "curatively treated basal cell carcinoma of the skin",
                                "curatively treated squamous cell carcinoma of the skin",
                                "carcinoma in situ of the cervix",
                                "carcinoma in situ of the breast",
                                "carcinoma in situ of the bladder"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with prior malignancies must be disease-free for >= two years",
                    "criterion": "prior malignancy disease-free interval",
                    "requirements": [
                        {
                            "requirement_type": "disease-free interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with low-risk prostate cancer on active surveillance are eligible",
                    "criterion": "low-risk prostate cancer on active surveillance",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential must agree to have a negative serum pregnancy test within 24 hours prior to treatment start; women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study treatment, and through at least 5 months after the last dose of study drug; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; sexually active men of reproductive potential who are partners of women with reproductive potential must also agree to use adequate contraception prior to the study, for the duration of study participation, and through at least 7 months after the last dose of study drug; adequate methods of effective birth control include sexual abstinence (men, women); vasectomy; or a condom with spermicide (men) in combination with barrier methods, hormonal birth control or intrauterine device (IUD) (women)",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential must agree to have a negative serum pregnancy test within 24 hours prior to treatment start",
                    "criterion": "serum pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 24 hours prior to treatment start"
                        },
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study treatment, and through at least 5 months after the last dose of study drug",
                    "criterion": "contraception use (women of childbearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "contraception method",
                            "expected_value": [
                                "hormonal",
                                "barrier method of birth control",
                                "abstinence"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to study entry, for the duration of study treatment, and through at least 5 months after the last dose of study drug"
                        }
                    ]
                },
                {
                    "exact_snippets": "should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately",
                    "criterion": "pregnancy notification (women participants)",
                    "requirements": [
                        {
                            "requirement_type": "notification",
                            "expected_value": "inform treating physician immediately"
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": [
                                "become pregnant",
                                "suspect she is pregnant"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "sexually active men of reproductive potential who are partners of women with reproductive potential must also agree to use adequate contraception prior to the study, for the duration of study participation, and through at least 7 months after the last dose of study drug",
                    "criterion": "contraception use (men of reproductive potential with partners of reproductive potential)",
                    "requirements": [
                        {
                            "requirement_type": "contraception method",
                            "expected_value": "adequate contraception"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to the study, for the duration of study participation, and through at least 7 months after the last dose of study drug"
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate methods of effective birth control include sexual abstinence (men, women); vasectomy; or a condom with spermicide (men) in combination with barrier methods, hormonal birth control or intrauterine device (IUD) (women)",
                    "criterion": "acceptable methods of contraception",
                    "requirements": [
                        {
                            "requirement_type": "methods",
                            "expected_value": [
                                "sexual abstinence (men, women)",
                                "vasectomy",
                                "condom with spermicide (men) in combination with barrier methods, hormonal birth control or intrauterine device (IUD) (women)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be able to swallow oral medications",
            "criterions": [
                {
                    "exact_snippets": "Patients must be able to swallow oral medications",
                    "criterion": "ability to swallow oral medications",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have received prior radiation therapy, chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, tumor infiltrating lymphocyte [TIL], lymphokine-activated killer [LAK] or gene therapy), or hormonal therapy for their brain tumor; glucocorticoid therapy is allowed",
            "criterions": [
                {
                    "exact_snippets": "must not have received prior radiation therapy ... for their brain tumor",
                    "criterion": "prior radiation therapy for brain tumor",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have received prior ... chemotherapy ... for their brain tumor",
                    "criterion": "prior chemotherapy for brain tumor",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have received prior ... immunotherapy ... for their brain tumor",
                    "criterion": "prior immunotherapy for brain tumor",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have received prior ... therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, tumor infiltrating lymphocyte [TIL], lymphokine-activated killer [LAK] or gene therapy) ... for their brain tumor",
                    "criterion": "prior therapy with biologic agent for brain tumor",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have received prior ... hormonal therapy for their brain tumor",
                    "criterion": "prior hormonal therapy for brain tumor",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "glucocorticoid therapy is allowed",
                    "criterion": "glucocorticoid therapy",
                    "requirements": [
                        {
                            "requirement_type": "current or prior use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients receiving any other investigational agents are ineligible",
            "criterions": [
                {
                    "exact_snippets": "Patients receiving any other investigational agents are ineligible",
                    "criterion": "receipt of investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a history of severe hypersensitivity reaction to any monoclonal antibody are ineligible",
            "criterions": [
                {
                    "exact_snippets": "history of severe hypersensitivity reaction to any monoclonal antibody",
                    "criterion": "hypersensitivity reaction to monoclonal antibody",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active liver disease or active hepatitis, or psychiatric illness/social situations that would limit compliance with study requirements, are ineligible",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled intercurrent illness",
                    "criterion": "intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "ongoing or active infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "ongoing or active"
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina pectoris",
                    "criterion": "angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active liver disease",
                    "criterion": "liver disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis",
                    "criterion": "hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness/social situations that would limit compliance with study requirements",
                    "criterion": "psychiatric illness or social situation limiting compliance",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who require therapy with systemic immunosuppressive drugs except corticosteroids are ineligible",
            "criterions": [
                {
                    "exact_snippets": "Patients who require therapy with systemic immunosuppressive drugs except corticosteroids are ineligible",
                    "criterion": "requirement for systemic immunosuppressive drugs (except corticosteroids)",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a history of active autoimmune disease requiring treatment in the past 2 years are ineligible",
            "criterions": [
                {
                    "exact_snippets": "history of active autoimmune disease requiring treatment in the past 2 years",
                    "criterion": "active autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time_since_treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents through 1 week after receiving the last dose of study drugs",
            "criterions": [
                {
                    "exact_snippets": "Pregnant women are excluded from this study",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding should be discontinued if the mother is treated with these agents through 1 week after receiving the last dose of study drugs",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "duration after last dose",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who are known to be human immunodeficiency virus (HIV) positive are ineligible",
            "criterions": [
                {
                    "exact_snippets": "Patients who are known to be human immunodeficiency virus (HIV) positive are ineligible",
                    "criterion": "HIV status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a history of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to valacyclovir, acyclovir, or temozolomide are ineligible; the valacyclovir and temozolomide package inserts can be referenced for more information",
            "criterions": [
                {
                    "exact_snippets": "history of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to valacyclovir, acyclovir, or temozolomide",
                    "criterion": "hypersensitivity or allergic reactions to compounds similar to valacyclovir, acyclovir, or temozolomide",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}